单位：[1]Department of Gastrointestinal Oncology, Peking University Cancer Hospital andInstitute, Beijing, China[2]Department of Oncology, Tongji Hospital, Tongji MedicalCollege, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院肿瘤科[3]Departmentof medicine, Nanjing Geneseeq Technology Inc., Nanjing, China[4]National CancerCenter/National Clinical Research Center for Cancer/Cancer Hospital & ShenzhenHospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen, China
Major Program of National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [91959205]; National Key Research and Development Program of China [2017YFC1308900]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81802327]
第一作者单位：[1]Department of Gastrointestinal Oncology, Peking University Cancer Hospital andInstitute, Beijing, China
推荐引用方式(GB/T 7714)：
C. Zhang,Z. Chen,Y. Chen,et al.Liquid biopsy forecasted disease progression and indicated therapeutic improvement for gastric cancer patients receiving HER2-targeted regimen[J].ANNALS OF ONCOLOGY.2020,31:S925-S926.doi:10.1016/j.annonc.2020.08.1995.
APA：
C. Zhang,Z. Chen,Y. Chen,X. Chong,T. Sun...&L. Shen.(2020).Liquid biopsy forecasted disease progression and indicated therapeutic improvement for gastric cancer patients receiving HER2-targeted regimen.ANNALS OF ONCOLOGY,31,
MLA：
C. Zhang,et al."Liquid biopsy forecasted disease progression and indicated therapeutic improvement for gastric cancer patients receiving HER2-targeted regimen".ANNALS OF ONCOLOGY 31.(2020):S925-S926
医学